We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
MRC Technology, Daiichi Sankyo form Drug Discovery Collaboration
News

MRC Technology, Daiichi Sankyo form Drug Discovery Collaboration

MRC Technology, Daiichi Sankyo form Drug Discovery Collaboration
News

MRC Technology, Daiichi Sankyo form Drug Discovery Collaboration

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "MRC Technology, Daiichi Sankyo form Drug Discovery Collaboration"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

MRC Technology announced it has established a drug discovery collaboration with global pharmaceutical company, Daiichi Sankyo. The agreement will focus on the identification and selection of novel drug targets with the potential to become potent and selective therapeutics including oncology, cardiovascular and metabolic diseases.

Under the terms of the agreement, MRC Technology will provide Daiichi Sankyo with details of potential drug targets sourced from academia. Daiichi Sankyo will have the opportunity to work with MRC Technology, who is responsible for screening followed by hit validation and future optimization of selected targets, as part of a collaborative project team. The project provides an ideal opportunity to combine the traditional strengths in drug discovery and development of Daiichi Sankyo with the rich knowledge of targets and disease biology available in academia provided by MRC Technology’s Centre for Therapeutics Discovery.

Justin Bryans, MRC Technology’s Director of Drug Discovery said, “Our aim is to translate early stage academic research into new therapeutic opportunities. Collaborating with Daiichi Sankyo early in this process means we can tap into their wealth of drug discovery experience with the view to generating novel chemical entities faster.”

The collaboration agreement was facilitated by MRC Technology’s agent in Japan, Summit Pharmaceuticals International (SPI). 

Target information and financial terms of the agreement have not been disclosed.

Advertisement